<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712097</url>
  </required_header>
  <id_info>
    <org_study_id>GO42909</org_study_id>
    <secondary_id>2020-005239-53</secondary_id>
    <nct_id>NCT04712097</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy</brief_title>
  <official_title>Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of mosunetuzumab in combination with&#xD;
      lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in&#xD;
      participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at&#xD;
      least one line of prior systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) according to 2014 Lugano Response Criteria</measure>
    <time_frame>From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS as Determined by the Investigator</measure>
    <time_frame>From randomization to the first occurrence of disease progression or death from any cause (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization to death from any cause (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>From the first occurrence of a documented objective response (complete response or partial response) to disease progression or death from any cause, whichever occurs first (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete Reponse (CR)</measure>
    <time_frame>From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Physical Functioning and Fatigue, as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Lymphoma Symptoms, as Measured by the Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of M + Len</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of M + Len</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs)</measure>
    <time_frame>Up to approximately 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNALT)</measure>
    <time_frame>From randomization to the first documented administration of a new anti-lymphoma treatment (up to approximately 8 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Relapsed or Refractory Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>M + Len</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R + Len</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 6, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab</intervention_name>
    <description>Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12</description>
    <arm_group_label>M + Len</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)</description>
    <arm_group_label>M + Len</arm_group_label>
    <arm_group_label>R + Len</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11</description>
    <arm_group_label>R + Len</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tociluzumab</intervention_name>
    <description>Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events</description>
    <arm_group_label>M + Len</arm_group_label>
    <arm_group_label>R + Len</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Histologically documented CD20+ FL (Grades 1-3a)&#xD;
&#xD;
          -  Requiring systemic therapy assessed by investigator based on tumor size and/or Groupe&#xD;
             d'Etude des Lymphomes Folliculaires criteria&#xD;
&#xD;
          -  Received at least one prior systemic lymphoma therapy, which included prior&#xD;
             immunotherapy or chemoimmunotherapy&#xD;
&#xD;
          -  Availability of a representative tumor specimen and the corresponding pathology report&#xD;
             at the time of relapse/persistence for confirmation of the diagnosis of FL.&#xD;
             Pretreatment sample of at least 1 core-needle, excisional or incisional tumor biopsy&#xD;
             is required. Cytological or fine-needle aspiration samples are not acceptable. Fresh&#xD;
             pretreatment biopsy is preferred. Patients who are unable to undergo biopsy procedures&#xD;
             may be eligible for study enrollment if an archival tumor tissue sample (preferably&#xD;
             from the most recent relapse/persistence) as paraffin blocks or at least 15 unstained&#xD;
             slides, or in accordance with local regulatory requirements, can be sent to the&#xD;
             Sponsor.&#xD;
&#xD;
          -  Adequate hematologic function (unless due to underlying lymphoma, per the&#xD;
             investigator)&#xD;
&#xD;
          -  Agreement to comply with all local requirements of the lenalidomide risk minimization&#xD;
             plan, which includes the global pregnancy prevention program.&#xD;
&#xD;
          -  For women of childbearing potential: Agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use 2 adequate methods of contraception, including at&#xD;
             least 1 method with a failure rate of &lt; 1% per year, for at least 28 days prior to Day&#xD;
             1 of Cycle 1, during the treatment period (including periods of treatment&#xD;
             interruption), and for at least 28 days after the last dose of lenalidomide, 3 months&#xD;
             after the final dose of tocilizumab (if applicable), mosunetuzumab, and 12 months&#xD;
             after final dose of rituximab. Women must refrain from donating eggs during this same&#xD;
             period.&#xD;
&#xD;
          -  For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures and agreement to refrain from donating sperm, as defined: With&#xD;
             female partners of childbearing potential or pregnant female partners, men must remain&#xD;
             abstinent or use a condom during the treatment period and for at least 28 days after&#xD;
             last dose of lenalidomide, 3 months after the final dose of tocilizumab (if&#xD;
             applicable), mosunetuzumab and 12 months after the final dose of rituximab. Men must&#xD;
             refrain from donating sperm during this same period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade 3b FL&#xD;
&#xD;
          -  History of transformation of indolent disease to diffuse-large B cell lymphoma&#xD;
&#xD;
          -  Documented refractoriness to lenalidomide, defined as no response (partial response or&#xD;
             complete response) or relapse within 6 months of therapy&#xD;
&#xD;
          -  Active or history of CNS lymphoma or leptomeningeal infiltration&#xD;
&#xD;
          -  Prior standard or investigational anti-cancer therapy as specified: Lenalidomide&#xD;
             exposure within 12 months prior to Day 1 of Cycle 1; Chimeric antigen receptor T cell&#xD;
             therapy within 30 days prior to Day 1 of Cycle 1; Radioimmunoconjugate within 12 weeks&#xD;
             prior to Day 1 of Cycle 1; Monoclonal antibody or antibody-drug conjugate within 4&#xD;
             weeks prior to Cycle 1 Day 1; Treatment with any anti-cancer agent (investigational or&#xD;
             otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to&#xD;
             first dose of study treatment&#xD;
&#xD;
          -  Clinically significant toxicity (other than alopecia) from prior treatment that has&#xD;
             not resolved to Grade &lt;/= 1 (per National Cancer Institute Common Terminology Criteria&#xD;
             for Adverse Events, Version 5.0) prior to Day 1 of Cycle 1&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications, including, but not limited to&#xD;
             prednisone (&gt; 20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis&#xD;
             factor agents within 2 weeks prior to Day 1 of Cycle 1&#xD;
&#xD;
          -  History of solid organ transplantation&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reaction to humanized, chimeric or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  Known sensitivity or allergy to murine products&#xD;
&#xD;
          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary (CHO)&#xD;
             cells or any component of the mosunetuzumab, rituximab, tocilizumab, lenalidomide, or&#xD;
             thalidomide formulation, including mannitol&#xD;
&#xD;
          -  History of erythema multiforme, Grade &gt;/= 3 rash, or blistering following prior&#xD;
             treatment with immunomodulatory derivatives&#xD;
&#xD;
          -  History of interstitial lung disease, drug-induced pneumonitis, and autoimmune&#xD;
             pneumonitis&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, or other infection, or any major episode of&#xD;
             infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1&#xD;
&#xD;
          -  Known or suspected chronic active Epstein-Barr virus (EBV) infection&#xD;
&#xD;
          -  Known or suspected history of hemophagocytic lymphohistiocytosis&#xD;
&#xD;
          -  Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             or cirrhosis&#xD;
&#xD;
          -  Active Hepatitis B infection&#xD;
&#xD;
          -  Active Hepatitis C infection&#xD;
&#xD;
          -  Known history of HIV positive status&#xD;
&#xD;
          -  History of progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before first dose of study&#xD;
             treatment or anticipation that such a live attenuated vaccine will be required during&#xD;
             the study&#xD;
&#xD;
          -  Other malignancy that could affect compliance with the protocol or interpretation of&#xD;
             results&#xD;
&#xD;
          -  Active autoimmune disease requiring treatment&#xD;
&#xD;
          -  History of autoimmune disease, including, but not limited to: myocarditis,&#xD;
             pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
             syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or&#xD;
             glomerulonephritis&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Contraindication to treatment for thromboembolism prophylaxis&#xD;
&#xD;
          -  Evidence of any significant, uncontrolled concomitant disease that could affect&#xD;
             compliance with the protocol or interpretation of results, including, but not limited&#xD;
             to, significant cardiovascular disease (e.g., New York Heart Association Class III or&#xD;
             IV cardiac disease, myocardial infarction within the previous 6 months, unstable&#xD;
             arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive&#xD;
             pulmonary disease or history of bronchospasm)&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of&#xD;
             Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or lactating or intending to become pregnant during the study&#xD;
&#xD;
          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             investigator's judgment, precludes the patient's safe participation in and completion&#xD;
             of the study, or which could affect compliance with the protocol or interpretation of&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID: GO42909 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University; Wash Uni. Sch. Of Med</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Haematology Clinical Trials</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Mie</city>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penza Regional Oncology Dispensary</name>
      <address>
        <city>Penza</city>
        <zip>440071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Universtiy Hospital; Division of Hematology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

